Report Overview

The Brazil Peptic Ulcer Drug size stood at USD xx million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

A peptic ulcer is a round or oval sore where the lining of the stomach or duodenum has been eaten away by stomach acid and digestive juices. Peptic ulcers can result from helicobacter pylori infection or from drugs that weaken the lining of the stomach or duodenum. Drugs used for the treatment of peptic ulcers include those that reduce gastric ulcer secretion, such as PPI and H2 receptor antagonists and acid neutralization agents such as antacids and antibiotics against H. pylori infection. However, these drugs are often used in combination for effective treatment.



Market Drivers

The major cause of the increasing prevalence of peptic ulcers is the infection from H. Pylori bacterium and rising intake of NSAIDs among the population. Also, peptic ulcer disease is predominantly affecting the older population, with the peak incidence occurring between 55 and 65 years of age. Therefore, apart from the rising prevalence of peptic ulcer disease, a growing geriatric population is contributing to the expansion of the market during the forecast period.

The rising prevalence of peptic ulcer disease, is propelling the key industry players to invest in the R&D activities. This results in the new drug launches for the treatment of peptic ulcer disease which has a positive impact on market growth.

Major Ulcer type

Based on ulcer type, the peptic ulcer drugs market is segmented into gastric ulcer and duodenal ulcer. The duodenal ulcer segment is expected to lead the market during the forecast period. The growing prevalence of duodenal ulcers, along with the rising awareness about therapeutic launches for its treatment is some of the factors attributable to its dominance during the forecast period.